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Clinical and morphological predictors of outcome in
older aplastic anemia patients treated with 
eltrombopag
Treatment of aplastic anemia (AA) in the elderly is partic-
ularly challenging due to higher toxicity and lower efficacy
of the available therapies. In fact, 30-40% of patients eligi-
ble for intensive immunosuppressive treatment (IST) with
horse anti-thymocyte globulin (ATG) plus cyclosporine
(CyA) will relapse and only a few cases would be candi-
dates for hematopoietic stem cell transplant (HSCT).1,2
Moreover, ATG might be contraindicated in frail patients or
in those with infectious comorbidities, and CyA alone is of
limited benefit.3,4 Recently, prospective trials show the clin-
ical efficacy of eltrombopag in refractory/relapsed AA, with
up to 40% hematologic improvement,5 and, intriguingly,
persistent remission upon discontinuation in robust
responders.6 Moreover, eltrombopag was added to front-
line IST, with an overall response rate exceeding 80%.7
Clinical and laboratory characteristics predicting eltrom-
bopag response in AA are still largely unknown, and data
about real-life use of this drug are scarce. Here we analyzed
the baseline hematologic and morphological (bone marrow
aspirate and trephine) variables and clinical course of 49
AA cases treated with eltrombopag at two tertiary hemato-
logic institutions in the UK, from January 2012 to January
2018. We focused on efficacy, safety, impact on disease out-
come, and on potential clinical and laboratory predictors of
treatment response (Online Supplementary Methods).
Median age was 67 years [interquartile range (IQR): 50.5-
71.5, 82% >60 years], 56% of cases had severe or very
severe AA, and the majority were either red cell or platelet
transfusion dependent (Table 1). Endogenous erythropoi-
etin (EPO) and thrombopoietin (TPO) levels were markedly
elevated in all cases, and telomere length (TL) reduced
(<10th percentile) in 11. Regarding bone marrow (BM) fea-
tures, all cases displayed reduced cellularity; the relative
percentage of lymphoid cells was >10% in 20 cases, with
no clonal lymphoid infiltrate or cases of T-cell large granu-
lar lymphocytic (TLGL) leukemia by immunohistochem-
istry or immunophenotyping. Cytogenetics were abnormal
in four patients (2 with del13q, one each with trisomy 8
and loss of Y), and failed in eight cases (16%) of whom one
showed presence of the +8 by fluorescence in situ
hybridization (FISH). Paroxysmal nocturnal hemoglobin-
uria (PNH) clone was detected in 32 patients (65%), and
clone size was <1% in 11 cases, 1-10% in 12, 10-50% in 5,
>50% in 3 cases (one requiring eculizumab). Seven patients
were treatment naïve and 42 had received prior therapy
(median: 1; range: 1-3), of whom eight patients had
relapsed and 34 were refractory AA (Online Supplementary
Figure S1). The median time from diagnosis to eltrombopag
was 330 days (IQR: 108-695), shorter for the treatment
naïve group. Patients received eltrombopag for a median of
four months (range: 3.5-30 months) at median dose of 150
mg/day, and CyA was continued in three patients. Overall
11 patients (22%) responded to eltrombopag, nine partial
response (PR) and two complete response (CR) according
to the criteria of the European Group for Blood and
Marrow Transplantation (EBMT) (first response) at 12
weeks. Six patients converted their PR into CR (best
response) on continuing treatment. Mean time to first
response was 4.4+2 months and to best response was
12.3+10.5 months. Interestingly, all responders attained tri-
lineage hematologic improvement and robust response, as
by National Institutes of Health criteria. Mean Hb level
increase from baseline was 34+12.4 g/L, platelet count
increase was 80+53x109/L, and ANC increase
1.25+0.95x109/L (P<0.001, P<0.001, and P=0.02, respec-
tively). Moreover, 21% and 14% cases became red cell and
platelet transfusion independent, respectively. BM re-eval-
uation after eltrombopag (n=25) showed significantly
increased cellularity (30+26% vs. 16+13%;  P=0.004), more
prominent in responders, and one responding patient dis-
played increased fibrosis (from MF0 to MF2). Considering
PNH clone size dynamic after eltrombopag treatment,
median granulocyte size increased in ten cases (mean
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Table 1. Baseline clinical and laboratory characteristics of aplastic
anemia patients enrolled.
                                                                            Patients N=49
Age years, median (range)                                                67 (15-84)
Gender F/M                                                                                22/27
AA type                                                                                             
acquired N(%)                                                                      48 (98)
inherited N(%)                                                                       1 (2)
Overlapping MDS N(%)                                                       6 (12)
AA severity                                                                                       
moderate N(%)                                                                    22 (44)
severe N(%)                                                                          14 (29)
very severe N(%)                                                                 13 (27)
Hb g/L, median (range)                                                     88 (41-129)
PLT x109/L, median (range)                                                18 (1-83)
ANC x109/L, median (range)                                                0,8 (0-4)
Transfusion dependence                                                            
RBC N(%)                                                                               43 (88)  
PLT N(%)                                                                                42 (86)
EPO levels (N=32 ,65%), median (range)                 541 (13-2250)
TPO levels (N=10,20%), median (range)                 1888 (148-3464)
PNH clones positivity N(%)                                                 32 (65)
Telomere length (N=23,47%)
Normal N(%)                                                                         12 (52)
<10 percentile N(%)                                                            6 (26)
<1 percentile N(%)                                                              5 (22)
BM features (N=46, 94%)                                                           
cellularity %                                                                          11 (3-40)
MF0 N(%)                                                                              23 (51)
MF1 N(%)                                                                              23 (49)
MGK                                                                                                
absent N(%)                                                                        22 (48)
reduced N(%)                                                                     18 (39)
dysplastic N(%)                                                                    4 (9)
normal N(%)                                                                         2 (4)
Lymphoid infiltrate %                                                           10 (0-60)
Cytogenetic abnormalities                                                     4 (8)
Normal                                                                                    37 (76)
Failed                                                                                        8 (16)
Abnormal*                                                                                4 (8)
*del13q (N=2); trisomy 8; delY. Of the 4 patients with some dysplastic megakary-
ocytes, the percentage was <10% and none presented with cytogenetics abnormal-
ities so that myelodysplastic syndrome (MDS) diagnosis could be excluded. AA:
aplastic anemia; Hb: hemoglobin; PLT: platelets; RBC: red blood cells; ANC: absolute
neutrophil counts; EPO: erythropoietin; TPO: thrombopoietin; BM: bone marrow;
PNH: paroxysmal nocturnal hemoglobinuria. MF0 or MF1 indicate the fibrosis
grade according to the World Health Organization (MF0 no fibrosis; MF1 sparse reti-
culin fibers); MGK: megakaryocyte; N: number.
increase 12%) and decreased in eight (mean decrease 11%)
while all other patients showed stable clones before and
after eltrombopag; no relationships were observed with
eltrombopag response. Regarding predictors of response
(Table 2), overall response (OR) was significantly related
with a moderate disease, lower BM lymphoid percentage,
and a smaller PNH clone. Considering previous therapies,
treatment naïve cases showed significantly better OR com-
pared to relapse/refractory patients (42% vs. 15%;  P=0.03).
Refractory cases showed a lower OR compared to relapsed
ones [17.6% vs. 37.5%; not significant (ns)], particularly
among CyA-treated patients (7% vs. 18%; P=0.05). Finally,
among those tested for TL, patients with TL >1st percentile
showed a higher OR (22.2%) compared to the others (0%),
although this difference was not significant. As regards
safety, we observed mostly grade I/II adverse events in up
to 29% of cases; 11 patients are still on treatment, whereas
38 patients discontinued eltrombopag after a median of
four months (range: 1-32 months) (Online Supplementary
Results). Three patients relapsed after 7, 15 and 34 months
of treatment, and received various therapies (Online
Supplementary Figure S1). The first case was then treated
with danazol and reached PR. The second case had con-
comitant autoimmune thrombocytopenia and was treated
with steroids and intravenous immunoglobulin with
platelet count recovery, and then re-challenged with
eltrombopag until CR. The third patient received CyA and
then tacrolimus with intolerance/no response, and contin-
ues to be transfusion dependent. Further therapies for NR
cases are detailed in Online Supplementary Figure S1.
Nineteen patients (39%) died, and median OS from the
beginning of eltrombopag was nine months (range: 4-54
months). Patients died because of progressive disease com-
plications including sepsis (n=10), severe cytopenias with
multi-organ failure (n=7), chest fungal infection (n=1), and
bacterial pneumonia (n=1). OS (censored for HSCT) was
significantly longer in patients responding to eltrombopag
[33.3 (95%CI: 21.4-45.2) vs. 7.5 (4.07-10.9) months;
P=0.005], in those with moderate AA (at diagnosis and
before eltrombopag treatment; P=0.001 and P=0.01), and
in the presence of a PNH clone (P=0.05) (Figure 1). Finally,
patients with normal or reduced BM megakaryocytes
showed a better outcome compared to cases with absent
megakaryocytes (84% vs. 41%; P=0.001); likewise, patients
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Figure 1. Overall survival in aplastic anemia patients. Overall survival by
Kaplan-Meyer method in eltrombopag-treated patients divided according to
(A) response to eltrombopag (P=0.005), (B) disease severity (P=0.001), and
(C) paroxysmal nocturnal hemoglobinuria (PNH) positivity (P=0.05) at the
time of eltrombopag initiation. CR: complete responders; PR: partial respon-
ders; NR: non-responders. 
Table 2. Response evaluation: relationship with baseline clinical and
laboratory characteristics. 
                                                            ORR N=11              NR N=38
Age years, median(range)                         69 (31-84)                  66(15-77)
Gender F/M                                                          5/6                             17/21
AA severity at eltrombopag initiation                                                    
moderate N(%)                                              8 (73)                       9 (24)*
severe N(%)                                                   2 (18)                        15 (39)
very severe N(%)                                            1 (9)                         14 (37)
Overlapping MDS N(%)                                   1 (9)                          5 (13)
Hb g/L, median(range)                              87 (41-109)               88 (63-129)
PLT x109/L, median(range)                          11 (2-49)                   18 (1-83)
ANC x109/L, median(range)                        0.9 (0-2.4)               0.77 (0.01-4)
Transfusion dependence                                                                        
RBC N(%)                                                        9 (82)                        34 (89)
PLT N(%)                                                         6 (55)                        36 (95)
EPO levels, median(range)                    251 (55-1884)           662 (13-2250)
TPO levels, median(range)                  1526 (148-3464)      2040 (1126-2851)
PNH clone size %, median(range)        0.1 (0.01-3.4)         0.79 (0.01-97)**
BM features                                                     OR (10)                     NR (36)
Cellularity %, median(range)                     15 (3-30)                    8 (3-40)
MF0 N(%)                                                        5 (50)                        23 (64)
MF1 N(%)                                                          5 (50)                        13 (36)
MGK                                                                                                              
absent N(%)                                                   4 (40)                        18 (50)
reduced N(%)                                                5 (50)                        13 (36)
dysplastic N(%)                                             1 (10)                          3 (8)
normal N(%)                                                    0 (0)                           2 (6)
Lymphoid infiltrate %, median(range)     5 (0-30)                  10 (5-60)**
*P<0.005; **P<0.05. ORR: responders; NR: non-responders; N: number; AA: aplastic
anemia; F: female; M: male; MDS: myelodysplastic syndrome; Hb: hemoglobin; PLT:
platelets; ANC: absolute neutrophil counts; EPO: erythropoietin; TPO: thrombopoi-
etin; BM: bone marrow; PNH: paroxysmal nocturnal hemoglobinuria; RBC: red
blood cells; MGK: megakaryocyte. MF0 or MF1 indicate the fibrosis grade accord-




with TL >1% and normal karyotype also showed better
OS, although the difference was not significant.
In this real-world study, we report eltrombopag efficacy
in approximately 25% of AA cases, mostly relapsed after or
refractory to IST. Response was lower than that reported in
early phase studies6,7 likely mirroring the heterogeneity and
complexity of real-world series, and the older age in our
study. Our data are more similar to the recent French study
evaluating 46 cases treated outside clinical trials, that
showed trilineage hematologic improvement  in 27% IST
naïve and 34% refractory cases.8 Survival of older patients
with AA is only 38% at five years using IST with ATG and
CyA. Moreover, a large study from Sweden5 using CyA
alone in AA reported no survival difference compared to
supportive care alone. Hence the need for new approaches
to treatment in this older cohort of patients. We demon-
strate for the first time a favorable impact of non-severe dis-
ease, lower polyclonal BM lymphoid infiltrate, and of a
smaller PNH clone on the response to eltrombopag.
Previous studies showed inconsistent predictors of
response: in prospective trials, better OR has been associat-
ed with higher reticulocyte counts in refractory cases,6 and
with longer TL and younger age in naïve patients.7 Our
results, although preliminary and in a small series, suggest
that eltrombopag is more effective in the setting of less
severe BM exhaustion, when stem cell renewal capability
and residual cellularity are greater. This is in line with the
reported ability of eltrombopag to stimulate hematopoiesis
at the level of primitive hematopoietic cells.9,10 We found
that responders displayed higher cellularity and better
megakaryocytic morphology (i.e. reduced compared to
absent megakaryocytes), suggesting that eltrombopag may
act better in the presence of a greater bone marrow reserve.
Consistently, a possible impact of BM cellularity on OR has
been recently reported in primary immune thrombocy-
topenia patients.11 Moreover, we observed a better
response in patients with lower BM lymphoid percentage,
and in those previously responding to CyA. These findings
may reflect the influence of the immune system on OR and
might suggest a role for combining eltrombopag with IST
in these cases; data from the RACE trial (IST vs.
IST+eltrombopag front line) will possibly clarify this point.
More than one-third of patients died, with survival being
significantly related to response to eltrombopag and pres-
ence of less severe disease, suggesting that the BM stem cell
pool is critical for survival. Interestingly, OS significantly
correlated with PNH positivity, in line with recent reports
in a large cohort of patients with AA and myelodysplastic
syndrome.12 Although these observations need to be con-
firmed in prospective studies, they might be consistent
with the presence of a stronger immune surveillance
against disease progression in PNH-positive cases.12 
In our study, we confirmed that eltrombopag can be dis-
continued with persistent response and re-administered
after interruption obtaining a new response, in line with
previous reports in AA and ITP.6  In spite of the concerns
about clonal evolution during TPO-mimetics stimulation,
we did not observe disease transformation, not even in
patients with aberrant karyotype, except for one who
evolved to refractory cytopenia with multilineage dyspla-
sia. The limited follow up does not allow definitive conclu-
sions to be drawn, as the appearance of new cytogenetic
abnormalities, including chromosome 7 loss/partial dele-
tion, has been described after longer follow up.6 
In conclusion, here we describe a clinically challenging
elderly population, with high mortality and limited treat-
ment options beyond best supportive care. In this setting,
eltrombopag is an effective and safe option, with better
results in treatment naïve patients, non-severe disease, and
a lower BM lymphoid infiltrate. Finally, we showed that
eltrombopag impacts on disease natural history, prolonging
survival in responding patients.
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